This is the first human pharmacokinetic study on TMZ to quantify CSF penetration. The AUC(CSF)/AUC(plasma) ratio was 20%. Systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Ostermann et al. (2004) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: